Aims: Depression is an important issue in heart failure (HF). The study investigated whole-brain and regional brain glucose metabolism in HF patients and its association with depression comorbidity.
Methods And Results: Twenty-nine hospitalized patients with symptomatic systolic HF (left ventricular ejection fraction <40%), New York Heart Association (NYHA) class II-IV and mean age of 55.5 ± 12.0 years, had psychometric questionnaires before discharge and an F-FDG PET/CT brain scan after discharge. Semi-automated image analysis was performed on all cases and 30 matched controls. The metabolic parameter mean standardized uptake value (SUV ) was calculated for the whole brain and three brain regions implicated in depression pathogenesis. A standardized SUV was also estimated by dividing regional brain SUV with whole-brain SUV . Cases had lower average whole-brain SUV (3.90 ± 1.49 vs. 5.10 ± 1.35, P = 0.001) and average regional brain SUV (4.57 ± 2.31 vs. 9.96 ± 3.58, P < 0.001) compared to controls. Whole-brain SUV had a significant correlation with patient age, NYHA class, diabetes, creatinine levels, depression, and cognitive impairment. Regional brain SUV was correlated with whole-brain SUV and depression. The standardized SUV , in particular, was found to be a robust index that could differentiate HF patients with 'epiphenomenal' (>0.93) or 'real' (≤0.93) depression.
Conclusion: Heart failure patients with more severe disease showed whole-brain and regional brain hypometabolism in F-FDG PET/CT. Depressed HF patients (Beck Depression Inventory score >13) exhibited different metabolic patterns that could be used to differentiate between 'epiphenomenal' and 'real' depression. Namely, presence of whole-brain hypometabolism suggested 'epiphenomenal' depression, whereas absence suggested 'real' depression. Presence of significant relative regional brain hypometabolism enhanced the likelihood of 'real' depression diagnosis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/ejhf.1866 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Real-Time Tractography-Assisted Neuronavigation for Transcranial Magnetic Stimulation.
Hum Brain Mapp
January 2025
Department of Neuroscience and Biomedical Engineering, School of Science, Aalto University, Espoo, Finland.
State-of-the-art navigated transcranial magnetic stimulation (nTMS) systems can display the TMS coil position relative to the structural magnetic resonance image (MRI) of the subject's brain and calculate the induced electric field. However, the local effect of TMS propagates via the white-matter network to different areas of the brain, and currently there is no commercial or research neuronavigation system that can highlight in real time the brain's structural connections during TMS. This lack of real-time visualization may overlook critical inter-individual differences in brain connectivity and does not provide the opportunity to target brain networks.
View Article and Find Full Text PDFEffects of a flexibly delivered group-based acceptance and commitment therapy on reducing stress and enhancing psychological wellbeing in parents of school-age children during the COVID-19 pandemic: a quasi-experimental study.
Front Public Health
December 2024
School of Nursing, The Hong Kong Polytechnic University, Kowloon, Hong Kong SAR, China.
Introduction: COVID-19 has increased parental stress and significantly impacted the psychological well-being of individuals, especially parents of school-age children. Acceptance and Commitment Therapy posits that individuals can accept their unchangeable inner experiences (thoughts and feelings) while acting in ways aligned with their personal values, demonstrating effectiveness in reducing stress and improving psychological well-being, especially among parents of children with chronic illness. This study aimed to test the effectiveness of a group-based ACT, delivered flexibly, in improving stress and psychological well-being in parents with school-age children, regardless of their children's chronic conditions, within a real-world context.
View Article and Find Full Text PDFEffectiveness of 8-week Treatment with Glecaprevir/Pibrentasvir in Treatment-naïve or -experienced HCV Patients: Results from an Observational Retrospective Study in Real-life Settings (ODYSSEY).
J Gastrointestin Liver Dis
December 2024
Digestive Diseases and Liver Transplantation Center, Fundeni Clinical Institute, Bucharest, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
Background And Aims: Pan-genotypic ribavirin-free oral direct-acting antivirals, including the glecaprevir/pibrentasvir combination, are recommended for the treatment of most patients with chronic hepatitis C virus (HCV) infection. In Romania, the HCV-infected patient population receiving glecaprevir/pibrentasvir is not well characterized and data on treatment effectiveness is lacking. The ODYSSEY study aimed to provide insights into the characteristics and treatment outcomes of HCV-infected Romanian patients receiving 8-week therapy with glecaprevir/pibrentasvir.
View Article and Find Full Text PDFLactoferrin-modified nanoemulsions enhance brain-targeting and therapeutic efficacy of arctigenin against Toxoplasma gondii-induced neuronal injury.
Int J Parasitol Drugs Drug Resist
December 2024
Key Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, Molecular Medicine Research Center, College of Pharmacy, Yanbian University, Yanji, 133002, Jilin Province, China. Electronic address:
Toxoplasma gondii, a neurotropic protozoan parasite, affects the central nervous system and causes various neurological disorders. Previous studies have demonstrated that Arctigenin (AG) exhibits anti-T. gondii activity and reduces depression-like behaviors induced by T.
View Article and Find Full Text PDFDeveloping a Sleep Algxorithm to Support a Digital Medicine System: Noninterventional, Observational Sleep Study.
JMIR Ment Health
December 2024
Otsuka Pharmaceutical Development & Commercialization, Inc, 508 Carnegie Center Drive, Princeton, NJ, 08540, United States, 1 609 535 9035.
Background: Sleep-wake patterns are important behavioral biomarkers for patients with serious mental illness (SMI), providing insight into their well-being. The gold standard for monitoring sleep is polysomnography (PSG), which requires a sleep lab facility; however, advances in wearable sensor technology allow for real-world sleep-wake monitoring.
Objective: The goal of this study was to develop a PSG-validated sleep algorithm using accelerometer (ACC) and electrocardiogram (ECG) data from a wearable patch to accurately quantify sleep in a real-world setting.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!